Correspondence 0001493152-24-043771 from Sonnet BioTherapeutics Holdings, Inc. (SONN) (CIK 0001106838)
Sonnet BioTherapeutics Holdings, Inc. (SONN) (CIK 0001106838)
Date: Nov. 6, 2024 · CIK: 0001106838 · Accession: 0001493152-24-043771
AI Filing Summary & Sentiment
File numbers found in text: 333-282850
Letter
Re: Sonnet BioTherapeutics Holdings, Inc.
November 6, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-1, as amended File No. 333-282850
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Securities Act”), Chardan Capital Markets, LLC, as the representative of several underwriters, hereby joins in the request of Sonnet BioTherapeutics Holdings, Inc. for acceleration of the effective date of the above-referenced registration statement on Form S-1, as amended (the “Registration Statement”), so that it becomes effective as of 5:00 p.m. Eastern Time on Wednesday, November 6, 2024, or as soon as practicable thereafter.
Pursuant to Rule 460 of the General Rules and Regulations of the Securities Act, please be advised that there will be distributed to each underwriter, who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned has and will comply, and it has been informed or will be informed by any participating dealers that they have complied or will comply, with the requirements of Rule 15c2- 8 under the Securities Exchange Act of 1934, as amended.
[Signature Page to Follow]
Very truly yours,
Chardan Capital Markets, LLC
Show Raw Text
CORRESP
1
filename1.htm
November
6, 2024
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division of Corporation Finance
100
F Street, N.E.
Washington, D.C. 20549
Re:
Sonnet BioTherapeutics Holdings, Inc.
Registration Statement on Form S-1, as amended File No. 333-282850
Request for Acceleration of Effective Date
Ladies
and Gentlemen:
Pursuant
to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Securities Act”),
Chardan Capital Markets, LLC, as the representative of several underwriters, hereby joins in the request of Sonnet BioTherapeutics Holdings,
Inc. for acceleration of the effective date of the above-referenced registration statement on Form S-1, as amended (the “Registration
Statement”), so that it becomes effective as of 5:00 p.m. Eastern Time on Wednesday, November 6, 2024, or as soon as practicable
thereafter.
Pursuant
to Rule 460 of the General Rules and Regulations of the Securities Act, please be advised that there will be distributed to each underwriter,
who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies of the proposed form of
preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The
undersigned has and will comply, and it has been informed or will be informed by any participating dealers that they have complied or
will comply, with the requirements of Rule 15c2- 8 under the Securities Exchange Act of 1934, as amended.
[Signature
Page to Follow]
Very truly yours,
Chardan Capital Markets, LLC
on behalf of itself and as representative of the Underwriters
By:
/s/
Shai Gerson
Name:
Shai
Gerson
Title:
Managing Partner
[Signature
Page to Underwriters’ Acceleration Request]